Showing results (121-130 of 141) with videos related to
Sort By:
Pageof 15
Cancer Immunology Research|January 26, 2023
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung CancerKewen He, Hampartsoum B Barsoumian, Nahum Puebla-Osorio, et al.Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.Elife|November 9, 2021
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modelingJoseph D Butner, Geoffrey V Martin, Zhihui Wang, et al.Journal for Immunotherapy of Cancer|September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapyHari Menon, Dawei Chen, Rishab Ramapriyan, et al.JAMA Oncology|September 19, 2019
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal CancerDawei Chen, Hari Menon, Vivek Verma, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.The Lancet. Respiratory Medicine|October 23, 2020
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trialsWillemijn S M E Theelen, Dawei Chen, Vivek Verma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2019
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyDaniel R Gomez, Chad Tang, Jianjun Zhang, et al.Frontiers in Immunology|November 21, 2022
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer modelYun Hu, Sébastien Paris, Genevieve Bertolet, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinomaKelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.Pageof 15